Clarithromycin inhibits progeny virus production from human influenza virus-infected host cells.
In vitro effects of macrolide clarithromycin (CAM) on influenza A virus-infected cells were examined using plaque reduction assay by treating cells either before or after viral adsorption. The significant inhibitory effect on influenza virus infection was detected only when the cells were treated with CAM after viral adsorption. The predominant inhibitory effect was observed during 4-7th hour after viral adsorption using viral production assay. CAM did not exhibit inhibitory effects on influenza virus hemagglutination, membrane fusion and viral sialidase activities. These findings indicate that CAM acts on a middle to late stage of the viral replication cycle resulting in inhibition of progeny virus production from the infected cells.
Miyamoto
Daisei
D
Department of Biochemistry, University of Shizuoka School of Pharmaceutical Science, Shizuoka, Japan.
Hasegawa
Sayaka
S
Sriwilaijaroen
Nongluk
N
Yingsakmongkon
Sangchai
S
Hiramatsu
Hiroaki
H
Takahashi
Tadanobu
T
Hidari
Kazuya
K
Guo
Chao-Tan
CT
Sakano
Yuichi
Y
Suzuki
Takashi
T
Suzuki
Yasuo
Y
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002460:Cell Line; D017291:Clarithromycin / Q000494:pharmacology*; D004285:Dogs; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006385:Hemagglutination Inhibition Tests; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D009980:Influenza A virus / Q000187:drug effects*; D009439:Neuraminidase / Q000037:antagonists & inhibitors; D010948:Viral Plaque Assay; D014779:Virus Replication / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D004791:Enzyme Inhibitors; D009439:Neuraminidase; D017291:Clarithromycin